CorMedix Inc. (CRMD)
NASDAQ: CRMD · IEX Real-Time Price · USD
4.120
-0.160 (-3.74%)
At close: Jul 2, 2024, 4:00 PM
4.110
-0.010 (-0.24%)
After-hours: Jul 2, 2024, 5:23 PM EDT
CorMedix Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
82
Market Cap
226.43M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 65.41K | -125.53K | -65.74% |
Dec 31, 2021 | 190.94K | -48.30K | -20.19% |
Dec 31, 2020 | 239.23K | -44.04K | -15.55% |
Dec 31, 2019 | 283.27K | -146.53K | -34.09% |
Dec 31, 2018 | 429.80K | 100.47K | 30.51% |
Dec 31, 2017 | 329.33K | 105.22K | 46.95% |
Dec 31, 2016 | 224.11K | 13.98K | 6.65% |
Dec 31, 2015 | 210.13K | 20.86K | 11.02% |
Dec 31, 2014 | 189.27K | 187.27K | 9,358.97% |
Dec 31, 2013 | 2.00K | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Auna SA | 1.06B |
AngioDynamics | 324.01M |
Sutro Biopharma | 154.07M |
Aquestive Therapeutics | 51.50M |
Utah Medical Products | 49.04M |
Nanobiotix | 40.23M |
Molecular Partners AG | 7.64M |
Nyxoah | 5.57M |
CRMD News
- 26 days ago - CorMedix Inc. Announces CMS Grants Pass-Through Status to Defencath - GlobeNewsWire
- 5 weeks ago - CorMedix Inc. Announces Commercial Agreement With Top Tier Dialysis Provider - GlobeNewsWire
- 7 weeks ago - CorMedix Inc. to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - CorMedix Inc. Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - CorMedix Inc. To Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 9, 2024 - GlobeNewsWire
- 2 months ago - CorMedix Inc. Announces CMS Grants TDAPA to DefenCath - GlobeNewsWire
- 2 months ago - CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin) - GlobeNewsWire
- 2 months ago - CorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conference - GlobeNewsWire